Polycystic Ovary Syndrome (PCO)

Categories: Blood diseases, Endocrine diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Polycystic Ovary Syndrome

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 12 73 43 36 54 42 44 15 17 70
Polycystic Ovarian Syndrome 73 20 43 15 32
Polycystic Ovaries 12 29 54
Pcos 12 20 43
Polycystic Ovarian Disease 12 43
Stein-Leventhal Syndrome 12 43
Sclerocystic Ovaries 43 70
Multicystic Ovaries 12 43
Polycystic Ovary Syndrome, Susceptibility to 6
Sclerocystic Ovarian Degeneration 43
Sclerocystic Ovary Syndrome 43
Cystic Disease of Ovaries 43
Cystic Disease of Ovary 43
Stein-Leventhal Synd. 12
Polycystic Ovary 12
Cystic Ovaries 6
Pcod 43
Pco 43


External Ids:

Disease Ontology 12 DOID:11612
KEGG 36 H01739
ICD9CM 34 256.4
MeSH 44 D011085
NCIt 50 C26862
SNOMED-CT 67 69878008
ICD10 32 E28.2
UMLS 70 C0032460 C1136382

Summaries for Polycystic Ovary Syndrome

MedlinePlus Genetics : 43 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.Most women with polycystic ovary syndrome produce excess male sex hormones (androgens), a condition called hyperandrogenism. Having too much of these hormones typically leads to excessive body hair growth (hirsutism), acne, and male pattern baldness.Hyperandrogenism and abnormal levels of other sex hormones prevent normal release of egg cells from the ovaries (ovulation) and regular menstrual periods, leading to difficulty conceiving a child (subfertility) or a complete inability to conceive (infertility). For those who achieve pregnancy, there is an increased risk of complications and pregnancy loss. Due to irregular and infrequent menstruation and hormone abnormalities, affected women have an increased risk of cancer of the uterine lining (endometrial cancer).In polycystic ovary syndrome, one or both ovaries can contain multiple small, immature ovarian follicles that can appear as cysts on medical imaging. Normally, ovarian follicles contain egg cells, which are released during ovulation. In polycystic ovary syndrome, abnormal hormone levels prevent follicles from growing and maturing to release egg cells. Instead, these immature follicles accumulate in the ovaries. Affected women can have 12 or more of these follicles. The number of these follicles usually decreases with age.About half of all women with polycystic ovary syndrome are overweight or obese and are at increased risk of a fatty liver. Additionally, many women with polycystic ovary syndrome have elevated levels of insulin, which is a hormone that helps control blood sugar levels. By age 40, about 10 percent of overweight women with polycystic ovary syndrome develop abnormally high blood sugar levels (type 2 diabetes), and up to 35 percent develop prediabetes (higher-than-normal blood sugar levels that do not reach the cutoff for diabetes). Obesity and increased insulin levels (hyperinsulinemia) further increase the production of androgens in polycystic ovary syndrome.Women with polycystic ovary syndrome are also at increased risk for developing metabolic syndrome, which is a group of conditions that include high blood pressure (hypertension), increased belly fat, high levels of unhealthy fats and low levels of healthy fats in the blood, and high blood sugar levels. About 20 percent of affected adults experience pauses in breathing during sleep (sleep apnea). Women with polycystic ovary syndrome are more likely than women in the general popluation to have mood disorders such as depression.

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to ovarian cyst and hyperinsulinism, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is MSR1 (Macrophage Scavenger Receptor 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and HIF-1 signaling pathway. The drugs Orlistat and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary, and related phenotypes are endocrine/exocrine gland and reproductive system

Disease Ontology : 12 An ovarian dysfunction that is characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

GARD : 20 Polycystic ovarian syndrome (PCOS) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. Women with this condition typically have high levels of hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. The cause of PCOS is unknown, but probably involves a combination of genetic and environmental factors. Treatment for PCOS may involve birth control pills and medications for diabetes and infertility. Medicines called anti-androgens are also used to speed the growth of hair and clear acne.

MedlinePlus : 42 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

KEGG : 36 Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. Clinical manifestations include oligomenorrhea or amenorrhea, hirsutism, and frequently infertility. Clinical signs of PCOS include elevated luteinizing hormone (LH) and gonadotropin-releasing hormone (GnRH) levels, whereas follicle-stimulating hormone (FSH) levels are muted or unchanged. As a result of the increase in GnRH, stimulation of the ovarian theca cells, in turn, produces more androgens. Risk factors for PCOS in adults includes insulin resistance (IR), type 2 diabetes, obesity, and cardiovascular disease. PCOS can be described as an oligogenic disorder in which the interaction of a number of genetic and environmental factors determine the heterogeneous, clinical, and biochemical phenotype. Management of clinical manifestations of PCOS includes oral contraceptives for menstrual irregularities and hirsutism. Treatment options for infertility include clomiphene, laparoscopic ovarian drilling, gonadotropins, and assisted reproductive technology.

Wikipedia : 73 Polycystic ovary syndrome, or PCOS, is the most common endocrine disorder in women of reproductive age.... more...

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 638)
# Related Disease Score Top Affiliating Genes
1 ovarian cyst 32.4 PRL GNRH1 CYP19A1
2 hyperinsulinism 32.4 SHBG INSR INS IGF1 GNRH1
3 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 32.4 INSR INS IGF1
4 prediabetes syndrome 32.3 SHBG INSR INS IGF1 CAPN10
5 alopecia, androgenetic, 1 32.3 SHBG CYP21A2 CYP19A1
6 cytochrome p450 oxidoreductase deficiency 32.2 CYP21A2 CYP17A1
7 gestational diabetes 32.2 SHBG INSR INS CAPN10
8 lipid metabolism disorder 32.2 SHBG INSR INS CYP21A2
9 acne 32.2 SHBG PRL INS IGF1 CYP21A2
10 glucose intolerance 32.1 SHBG PRL INSR INS IGF1
11 anovulation 32.0 SHBG PRL INS IGF1 GNRH1 GDF9
12 ovarian hyperstimulation syndrome 32.0 SHBG INS GNRH1 CYP19A1 CYP11A1
13 hyperandrogenism 31.9 SHBG PRL INSR INS IGF1 GNRH1
14 ovarian disease 31.9 SHBG PRL INSR INS IGF1 GNRH1
15 infertility 31.9 SHBG PRL INS GNRH1 GDF9 CYP21A2
16 acanthosis nigricans 31.9 SHBG PRL INSR INS IGF1
17 amenorrhea 31.7 SHBG PRL INS IGF1 GNRH1 GDF9
18 hyperprolactinemia 31.6 SHBG PRL INS IGF1 GNRH1
19 insulin-like growth factor i 31.6 SHBG PRL INSR INS IGF1
20 hypothyroidism 31.5 SHBG PRL INS IGF1 GNRH1
21 sexual disorder 31.4 SHBG PRL INS IGF1 GNRH1
22 androgenic alopecia 31.4 SHBG PRL INS IGF1 CYP19A1
23 body mass index quantitative trait locus 11 31.3 SHBG INSR INS IGF1 FST CYP21A2
24 hypoglycemia 31.3 PRL INSR INS IGF1
25 galactorrhea 31.3 PRL IGF1
26 lipoid congenital adrenal hyperplasia 31.2 GNRH1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
27 sleep disorder 31.2 PRL INS IGF1
28 estrogen excess 31.1 SHBG PRL GNRH1 CYP19A1
29 acromegaly 31.0 SHBG PRL INS IGF1 GNRH1
30 precocious puberty 31.0 GNRH1 CYP21A2 CYP19A1
31 endometrial cancer 31.0 SHBG INS IGF1 GNRH1 GAS5 CYP19A1
32 goiter 31.0 PRL INS IGF1
33 bone resorption disease 31.0 INS IGF1 CYP19A1
34 fetal macrosomia 30.9 INSR INS IGF1
35 pituitary gland disease 30.9 PRL INS IGF1 GNRH1
36 male infertility 30.9 SHBG PRL GNRH1 CYP21A2 CYP19A1 CYP17A1
37 hypogonadism 30.9 SHBG PRL INS IGF1 GNRH1
38 endometrial disease 30.9 IGF1 GNRH1 CYP19A1
39 central precocious puberty 30.8 IGF1 GNRH1
40 type 2 diabetes mellitus 30.8 SHBG PRL INSR INS IGF1 GAS5
41 anorexia nervosa 30.8 SHBG PRL INS IGF1
42 breast disease 30.8 SHBG PRL IGF1 CYP19A1
43 androgen insensitivity syndrome 30.7 SHBG INS CYP17A1
44 thyroid gland disease 30.7 SHBG PRL INS IGF1
45 hyperthyroidism 30.7 SHBG PRL INS IGF1
46 aromatase deficiency 30.7 INS GNRH1 CYP19A1
47 gender identity disorder 30.6 CYP19A1 CYP17A1
48 leiomyoma 30.6 GNRH1 CYP19A1 CYP17A1
49 pseudohermaphroditism 30.5 CYP21A2 CYP19A1 CYP17A1 CYP11A1
50 psychosexual disorder 30.5 SHBG PRL

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:

Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:

pelvic pain

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.65 CAPN10 CYP11A1 CYP19A1 FST GDF9 GNRH1
2 reproductive system MP:0005389 9.32 CYP11A1 CYP17A1 CYP19A1 FST GDF9 GNRH1

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Simvastatin Approved Phase 4 79902-63-9 54454
Liraglutide Approved Phase 4 204656-20-2 44147092
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Tamoxifen Approved Phase 4 10540-29-1 2733526
Alogliptin Approved Phase 4 850649-61-5 11450633
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Citalopram Approved Phase 4 59729-33-8 2771
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
Drospirenone Approved Phase 4 67392-87-4 68873
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Glucagon Approved Phase 4 16941-32-5
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
Topiramate Approved Phase 4 97240-79-4 5284627
Iron Approved Phase 4 7439-89-6 23925 29936
Canagliflozin Approved Phase 4 842133-18-0
Testosterone Approved, Investigational Phase 4 58-22-0 6013
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
Cobalamin Experimental Phase 4 13408-78-1 6857388
Dexetimide Withdrawn Phase 4 21888-98-2
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
50 Hemostatics Phase 4

Interventional clinical trials:

(show top 50) (show all 698)
# Name Status NCT ID Phase Drugs
1 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
2 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
3 Adding L-carnitine in Clomiphene Resistant Pco Improves the Quality of Ovulation and the Pregnancy Outcome,a Randomized Clinical Trial Unknown status NCT01665547 Phase 4 l-carnitine
4 Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients Unknown status NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
5 Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Unknown status NCT03486626 Phase 4 Metformin
6 The Effect Of Vitamin D Replacement Therapy On Serum Leptin And Follicular Growth Pattern In Women With Resistant Polycystic Ovarian Syndrome Unknown status NCT03806036 Phase 4 Vitamin D;Clomiphene Citrate
7 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
8 Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome. Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
9 Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome Unknown status NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
10 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
11 Endometrial Scratching at Time of Laproscopic Ovarian Drilling in Women With Anovulatory Infertility Due to Polycystic Ovarian Syndrome (PCOS): Randomized Controlled Trial. Unknown status NCT02140398 Phase 4
12 The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS). Unknown status NCT01588873 Phase 4 oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
13 Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
14 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
15 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
16 Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome Unknown status NCT02344888 Phase 4 Clomiphene citrate and Prednisolone;Clomiphene citrate and folic acid
17 The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
18 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
19 A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
20 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
21 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
22 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
23 Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study Unknown status NCT02215135 Phase 4 Corifollitropin alfa
24 A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR® Versus FOLLISTIM® in Polycystic Ovarian Syndrome (PCOS) Patients Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
25 Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome Completed NCT00478504 Phase 4 Letrozole;Clomifene citrate
26 N-acetyl Cysteine as an Adjuvant Therapy to Laparoscopic Ovarian Drilling in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
27 A Clinical Trial to Measure the Effect of DHA-enriched Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat Content in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
28 Evaluate the Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4 clomiphene citrate with ethinyl esteradiol;clomiphene citrate with plasebo
29 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
30 Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome Completed NCT02802865 Phase 4 Clomiphene;Letrozole
31 Phytoestrogens as an Alternative to Estradiol in Reversing the Antiestrogenic Effect of Clomid on Endometrium in Ovulation Induction in Cases of Polycystic Ovarian Syndrome Completed NCT02352597 Phase 4 phytoestrogen;estradiol valerate;clomiphene citrate
32 The Effects of Treatment With Oral Contraceptive Pill Containing Ethinyl Estradiol-Cyproterone Acetate and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in Polycystic Ovarian Syndrome Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
33 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
34 The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome Completed NCT02122380 Phase 4 Sitagliptin;Placebo
35 Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success Completed NCT02606500 Phase 4 Elonva
36 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
37 Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation Completed NCT03352869 Phase 4 Exenatide;Metformin
38 Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4 HMG;rFSH
39 Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial Completed NCT01896492 Phase 4 NAC
40 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Completed NCT02483299 Phase 4 Metformin;Glucophage tablets and Victoza
41 Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role? Completed NCT03642600 Phase 4 dietary advice plus Liraglutide Pen Injector
42 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
43 Clomiphene Citrate Versus Tamoxifen for Induction of Ovulation in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial Completed NCT02479256 Phase 4 Clomiphene citrate;Tamoxifen Placebo;Tamoxifen;Clomiphene citrate placebo
44 Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome Completed NCT01899430 Phase 4 liraglutide;metformin
45 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
46 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
47 Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
48 Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
49 Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
50 Therapeutic Effect of Vitamin D3 Supplementation to Clomiphene Citrate Resistant Polycystic Ovary Syndrome Women Completed NCT04010942 Phase 4 Vit D;Metformin;Clomiphene

Search NIH Clinical Center for Polycystic Ovary Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cochrane evidence based reviews: polycystic ovary syndrome

Genetic Tests for Polycystic Ovary Syndrome

Genetic tests related to Polycystic Ovary Syndrome:

# Genetic test Affiliating Genes
1 Polycystic Ovaries 29

Anatomical Context for Polycystic Ovary Syndrome

MalaCards organs/tissues related to Polycystic Ovary Syndrome:

Ovary, Endothelial, Pituitary, Bone, Thyroid, Heart, Liver

Publications for Polycystic Ovary Syndrome

Articles related to Polycystic Ovary Syndrome:

(show top 50) (show all 15700)
# Title Authors PMID Year
Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. 61 54 6
14602801 2003
Comment: CAPN10 alleles are associated with polycystic ovary syndrome. 61 54 6
12161543 2002
Efficacy and safety of moxibustion in the treatment of infertility with polycystic ovary syndrome: A protocol of systematic review and meta-analysis. 61 42
33725936 2021
The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary syndrome. 42 61
33594056 2021
Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection? 61 42
33716989 2021
Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. 6
14574648 2003
Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. 6
11481585 2001
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. 6
11017071 2000
Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome. 61 54
20514429 2010
No association of the G972S polymorphism of the insulin receptor substrate-1 gene with polycystic ovary syndrome in lean PCOS women with biochemical hyperandrogenemia. 54 61
20012307 2010
C-reactive protein and homocysteine levels are associated with abnormal heart rate recovery in women with polycystic ovary syndrome. 61 54
19362308 2010
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome. 54 61
19376510 2010
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 61 54
19342032 2010
CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. 61 54
19324338 2010
Insulin resistance and overweight-obese women with polycystic ovary syndrome. 54 61
19903118 2010
Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. 54 61
20185515 2010
The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. 61 54
19171332 2010
Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome. 54 61
20103703 2010
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome. 54 61
20096985 2010
Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). 54 61
20008886 2010
Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. 54 61
19171337 2010
[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]. 54 61
20450755 2010
High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. 61 54
20080859 2010
Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. 61 54
20148738 2010
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. 54 61
19489873 2010
Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome. 61 54
20093255 2010
Decreased adiponectin levels in polycystic ovary syndrome, independent of body mass index. 54 61
19929617 2010
Serum retinol-binding protein 4 levels in nonobese women with polycystic ovary syndrome. 54 61
19028383 2010
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. 54 61
19111298 2010
Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. 54 61
19926323 2010
Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. 54 61
19892338 2010
Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. 61 54
20089616 2010
Adiponectin and resistin concentrations after glucose load in adolescents with polycystic ovary syndrome. 54 61
19639497 2010
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. 54 61
19019358 2010
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance]. 61 54
20367923 2010
Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS). 61 54
19438903 2010
Unilateral ovarian enlargement in adolescents with polycystic ovary syndrome: a variant of bilateral disease. 61 54
20432811 2010
[Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation]. 61 54
20209851 2009
Effects of polymorphisms of the sex hormone-binding globulin (SHBG) gene on free estradiol and bone mineral density. 61 54
19679209 2009
Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women. 54 61
19938957 2009
Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. 54 61
19905998 2009
Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. 54 61
19700156 2009
The relationship between follistatin and chronic low-grade inflammation in women with polycystic ovary syndrome. 61 54
19591997 2009
Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). 54 61
19389110 2009
Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. 61 54
20015405 2009
Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. 61 54
19596311 2009
Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. 54 61
19713424 2009
Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. 54 61
19654109 2009
Association of single nucleotide polymorphisms in adiponectin and its receptor genes with polycystic ovary syndrome. 54 61
20120899 2009
[The activity of platelet activating factor acetylhydrolase and its metabolic profile in patients with polycystic ovary syndrome]. 54 61
20067121 2009

Variations for Polycystic Ovary Syndrome

ClinVar genetic disease variations for Polycystic Ovary Syndrome:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CAPN10 NM_023083.4(CAPN10):c.471-187T>C SNV risk factor 5096 rs2975760 GRCh37: 2:241531163-241531163
GRCh38: 2:240591746-240591746

Expression for Polycystic Ovary Syndrome

Search GEO for disease gene expression data for Polycystic Ovary Syndrome.

Pathways for Polycystic Ovary Syndrome

GO Terms for Polycystic Ovary Syndrome

Cellular components related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.96 PRL INS
2 organelle membrane GO:0031090 8.8 CYP21A2 CYP19A1 CYP17A1

Biological processes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 PRL INSR INS IGF1 GDF9
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 INSR INS IGF1
3 activation of protein kinase B activity GO:0032148 9.61 INSR INS IGF1
4 positive regulation of mitotic nuclear division GO:0045840 9.58 INSR INS IGF1
5 sterol metabolic process GO:0016125 9.54 CYP21A2 CYP19A1 CYP11A1
6 amyloid-beta clearance GO:0097242 9.52 MSR1 INSR
7 positive regulation of glycolytic process GO:0045821 9.5 INSR INS IGF1
8 neuron projection maintenance GO:1990535 9.48 INSR INS
9 positive regulation of respiratory burst GO:0060267 9.46 INSR INS
10 steroid biosynthetic process GO:0006694 9.46 CYP21A2 CYP19A1 CYP17A1 CYP11A1
11 positive regulation of glycogen biosynthetic process GO:0045725 9.43 INSR INS IGF1
12 glucocorticoid biosynthetic process GO:0006704 9.13 CYP21A2 CYP17A1 CYP11A1
13 positive regulation of glucose import GO:0046326 8.92 INSR INS IGF1 CAPN10

Molecular functions related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.67 CYP21A2 CYP19A1 CYP17A1 CYP11A1
2 iron ion binding GO:0005506 9.62 CYP21A2 CYP19A1 CYP17A1 CYP11A1
3 hormone activity GO:0005179 9.56 PRL INS IGF1 GNRH1
4 monooxygenase activity GO:0004497 9.46 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5 cargo receptor activity GO:0038024 9.4 MSR1 INSR
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP21A2 CYP19A1 CYP17A1 CYP11A1
7 insulin-like growth factor receptor binding GO:0005159 8.8 INSR INS IGF1

Sources for Polycystic Ovary Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....